During the spring GTC 2023 symposium, Mitsui and NVIDIA announced the Tokyo-1 project. It is claimed to be the world's first generative AI supercomputer designed specifically for the pharmaceutical industry. Customers will be able to run large AI models on Tokyo-1 using NVIDIA BioNeMo software and services.
The supercomputer will be powered by Xeureka, an AI-assisted drug development company based in the United States at the end of 2023.
Tokyo-1's artificial intelligence models will aid in the creation of new medicinal structures. Workshops and training sessions will also be offered on the Tokyo-1 platform, as well as technical help from Xeureka and NVIDIA.
Researchers will be able to extend AI models to millions and billions of parameters in many areas, including protein structure prediction, as well as protein structure prediction. Major Japanese pharmaceutical companies, such as Astellas Pharma, Daiichi-Sankyo, and Ono Pharmaceutical, have already announced their intention to utilize Tokyo-1 in their projects.
If you notice an error, highlight it with the mouse and press CTRL + ENTER. | Can you write better? We welcome new authors.